| EMA number | EMEA/H/C/006215 |
| ATC code | Not yet assigned |
| Authorisation | 22 August 2024 |
| Revision | 1 |
Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy. Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy.